Screener
Dianthus Therapeutics DNTH Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Dianthus Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: Dianthus Therapeutics’s 10-Q, filed November 5, 2025. Open the filing →
- Filed
- Nov 5, 2025
- Fiscal quarter
- Q3 FY2025
- Calendar quarter
- Q3 2025
- Accession
- 0001193125-25-266920
FAQ
- What is Dianthus Therapeutics's return on equity?
- Dianthus Therapeutics (DNTH) reported return on equity of -28.6% in Q3 2025.
- How has Dianthus Therapeutics's return on equity changed year-over-year?
- Dianthus Therapeutics's return on equity decreased by 9.9% year-over-year, from -26% to -28.6%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Dianthus Therapeutics's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude